Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline

Executive Summary

Compared to its old oncology R&D lineup, Genentech's current cancer pipeline makes it clear that the company is embracing a new, riskier development strategy

You may also be interested in...

With A Novel Pipeline, Pfizer Tries A New Oncology Business Unit Too

With a lot of determination and a lot of licensing, Pfizer has managed to pack its oncology pipeline with novel mechanisms. Now the company is trying to innovate its business organization to make the most of what it has

Highlights Of The American Society Of Clinical Oncology, In Brief

Erbitux significantly prolongs survival in first-line NSCLC: The addition of Bristol-Myers Squibb/ImClone/Merck KGaA's Erbitux (cetuximab) to platinum-based chemotherapy significantly increased overall survival in first-line treatment of non-small cell lung cancer, the first targeted therapy to show a significant survival benefit in NSCLC patients across all histological subtypes. In the Phase III FLEX trial, presented at the June 1 ASCO plenary session, over 1,000 patients with stage IIIB or IV NSCLC were randomized to receive Erbitux plus chemotherapy or chemo alone. Median overall survival was 11.3 months for the Erbitux arm versus 10.1 months for chemotherapy alone. The sponsors are discussing with FDA their plans to use the data as the basis of a supplemental BLA filing, which they hope to submit at the end of this year. Erbitux is approved for treatment of metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-based regimens, and as a single agent for metastatic CRC in patients intolerant to irinotecan

AVADO Presented At ASCO; But After The Fanfare, What Does It Signify?

CHICAGO - With the positive results of Roche's AVADO study of Avastin in first-line metastatic breast cancer, Roche and Genentech have the value of having a placebo-controlled, double-blind confirmation of bevacizumab's use in that setting. But what the presentation of AVADO at the American Society of Clinical Oncology annual meeting really did was revive debate over the breast cancer approval and raise questions about proper use in that setting

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts